ArticleJournal of the American Heart Association2025
Association of Rate-Control and Antiarrhythmic Medication Use and Risk of Ischemic Stroke and Death in Patients on Dialysis With Atrial Fibrillation.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal heart rate in patients with atrial fibrillation: insights from the COOL-AF registry.Internal and emergency medicine · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIncident atrial fibrillation (AF) is common among adults with kidney failure treated with maintenance dialysis and is associated with poor clinical outcomes. Limited data exist informing treatment of AF among patients on dialysis. We aimed to describe the use of rate-control and antiarrhythmic medications for AF among patients on dialysis and associations of these medication use strategies with stroke and all-cause death.
methodsWe evaluated patients on dialysis with incident AF between 2010 and 2017 in the Kaiser Permanente Northern and Southern California integrated health care delivery systems. We characterized time-updated
resultsOf 2100 patients, 44.0% were newly prescribed rate-control medications, 4.6% were prescribed antiarrhythmic medications, 8.9% were prescribed both, and 42.9% were prescribed neither within 12 months of newly diagnosed AF. During a median 1.66 (interquartile range, 0.45-3.39) years, we observed 1406 composite events (stroke and death). Time-updated use of antiarrhythmics alone (adjusted hazard ratio [HR], 0.74 [95% CI, 0.57-0.96]) or with rate-control (adjusted HR, 0.72 [95% CI, 0.58-0.90]) was associated with lower stroke or death risk versus neither medication. Use of rate-control medications alone was not significantly associated with the composite outcome.
conclusionsAmong patients on dialysis with incident AF, use of antiarrhythmic medications may be associated with lower risk of stroke and death. Future randomized trials are needed to determine the efficacy and safety of antiarrhythmic medications in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.